The cyclotron saga continues.

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

ACTA: The SAGA Continues

ACTA is a comprehensive transaction framework that permits a transaction modeler to specify the e ects of extended transactions on each other and on objects in the database. ACTA allows the speci cation of (1) the interactions between transactions in terms of relationships between signi cant (transaction management) events, such as begin, commit, abort, delegate, split, and join, pertaining to ...

متن کامل

CHARISMA: the antiplatelet saga continues.

CHARISMA: The Antiplatelet Saga Continues To the Editor: We read with interest the Editorial by Norris and Barnett1 on the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. They conclude that aspirin is still the first choice in the secondary prevention of stroke, that clopidogrel is only marginally more effective than aspirin in ...

متن کامل

Pistorious at the Olympics: the saga continues.

The 2012 Summer Olympic Games will take place in London, from 27 July to 12 August. The most important sport competition in the world shapes up to be unprecedented in the overall number of participants, finally including ‘the fastest man on no legs’, Oscar Pistorious. Oscar Leonard Carl Pistorius was born in 1986 in South Africa with congenital absence of the fibula in both legs that were amput...

متن کامل

The Info - Gap / Maximin Saga Continues

On numerous occasions and in many articles I have formally shown (proved) that Info-Gap’s robustness model (Ben-Haim 1999, 2001, 2006) is a Maximin model (Wald 1945, 1950) par excellence and that it is fundamentally flawed in the way it handles severe uncertainty. Furthermore, I have shown that the Info-Gap/Maximin connection is not strictly mathematical in nature. Indeed, the conceptual framew...

متن کامل

Antidepressants: The Risk/Benefit Saga Continues

The dust hasn't so much settled as been whipped in new directions following the FDA's March 22, 2004, advisory and the October 15, 2004, black-box warning of increased suicidality risk in adolescents and children taking selective serotonin reuptake inhibitors (SSRIs) to treat depression.1 While various studies challenge the FDA warning and researchers inch closer to understanding serotonin's ro...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: BMJ

سال: 1990

ISSN: 0959-8138,1468-5833

DOI: 10.1136/bmj.300.6716.46-b